Centre for Research and Knowledge Transfer in Biotechnology,University of Zagreb,Rockefellerova 10,10000 Zagreb,Croatia.
School of Medicine, University of Zagreb,Šalata 3,10000 Zagreb,Croatia.
Epidemiol Infect. 2018 Aug;146(11):1372-1383. doi: 10.1017/S0950268818001693. Epub 2018 Jun 18.
Previously we reported on the HPIV2 genotype distribution in Croatia 2011-2014. Here we expand this period up to 2017 and confirm that G1a genotype has replaced G3 genotype from the period 2011-2014. Our hypothesis was that the G1a-to-G3 genotype replacement is an antibody-driven event. A cross-neutralisation with anti-HPIV2 sera specific for either G1a or G3 genotype revealed the presence of genotype-specific antigenic determinants. By the profound, in silico analyses three potential B cell epitopic regions were identified in the hemagglutinin neuraminidase (regions 314-361 and 474-490) and fusion protein (region 440-484). The region identified in the fusion protein does not show any unique site between the G1a and G3 isolates, five differentially glycosylated sites in the G1a and G3 genotype isolates were identified in epitopic regions of hemagglutinin neuraminidase. All positively selected codons were found to be located either in the region 314-316 or in the region 474-490 what indicates a strong positive selection in this region and reveals that these regions are susceptible to evolutionary pressure possibly caused by antibodies what gives a strong verification to our hypothesis that neutralising antibodies are a key determinant in the inherently complex adaptive evolution of HPIV2 in the region.
此前,我们报道了 2011 年至 2014 年克罗地亚的 HPIV2 基因型分布情况。在此,我们将时间延长至 2017 年,并证实 G1a 基因型已取代了 2011 年至 2014 年的 G3 基因型。我们的假设是,G1a 至 G3 基因型的替代是一种抗体驱动的事件。用针对 G1a 或 G3 基因型的抗 HPIV2 血清进行交叉中和实验,揭示了存在基因型特异性抗原决定簇。通过深入的计算机分析,在血凝素神经氨酸酶(区域 314-361 和 474-490)和融合蛋白(区域 440-484)中鉴定出三个潜在的 B 细胞表位区。融合蛋白中鉴定出的区域在 G1a 和 G3 分离株之间没有任何独特的位点,在血凝素神经氨酸酶的表位区鉴定出 G1a 和 G3 基因型分离株中有五个差异糖基化位点。所有被选择的密码子都位于 314-316 区域或 474-490 区域,这表明该区域存在强烈的正选择,并揭示了这些区域易受可能由抗体引起的进化压力的影响,这为我们的假设提供了有力的验证,即中和抗体是 HPIV2 在该区域固有复杂适应性进化的关键决定因素。